Skip to Content

Eli Lilly, O’Neal 'break through stigma’ of obstructive sleep apnea 

Eli Lilly, O’Neal 'break through stigma’ of obstructive sleep apnea  Lilly’s Zepbound was approved last year for the treatment of moderate-to-severe sleep apnea in adults with obesity

INDIANAPOLIS – Eli Lilly has a new partnership with NBA Hall of Famer and cultural icon Shaquille O’Neal to launch a nationwide campaign raising awareness about moderate-to-severe obstructive sleep apnea (OSA). 

The campaign aims to educate the public about symptoms and potential health impacts of moderate-to-severe OSA, a serious but often overlooked health condition that impacts 24 million people in the U.S., many of whom are overweight or living with obesity, the company says. 

"Moderate-to-severe obstructive sleep apnea is more than just snoring – it's a serious condition and it deserves serious attention," O'Neal said. "For years, I was tired all the time and didn't know why, but getting diagnosed made a real difference. I'm not always one to ask for help, and I know it can be difficult to speak up when something is impacting you. I'm here to say don't ignore moderate-to-severe OSA symptoms – talk to your doctor." 

Through a series of digital and media activations that build on Lilly's Don't Sleep on OSA campaign, O'Neal will encourage people to recognize the symptoms of moderate-to-severe OSA and take action by visiting DontSleepOnOSA.com and by talking to their health care provider. 

Late last year, the U.S. Food and Drug Administration approved Lilly’s Zepbound (tirzepatide) for the treatment of moderate-to-severe sleep apnea in adults with obesity to be used in combination with a reduced-calorie diet and increased physical activity. 

"Moderate-to-severe obstructive sleep apnea is a serious and often overlooked condition that affects millions of Americans," said Lina Polimeni, senior vice president and chief marketing officer, consumer, at Lilly. "By partnering with Shaquille O'Neal, someone who brings authenticity, relatability and cultural reach, we're aiming to break through the stigma and spark real conversations. This campaign, and the exciting work we're doing at Lilly, is about empowering people to recognize possible symptoms and take action." 

Comments

To comment on this post, please log in to your account or set up an account now.